Eventide Asset Management PRCT Position
Exited3-Fund ConvergenceEventide Asset Management exited their position in PROCEPT BioRobotics Corp (PRCT) in Q4 2025, after holding the stock for 6 quarters.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
PRCT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 13.6% of float with 2.6 days to cover, indicating significant bearish positioning against the stock.
About PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Full company profile →Short Interest
13.6%
2.6 days to cover
Eventide Asset Management PRCT Position History
Frequently Asked Questions
Does Eventide Asset Management own PRCT?
No. Eventide Asset Management exited their position in PROCEPT BioRobotics Corp (PRCT) in Q4 2025. They previously held the stock for 6 quarters.
How many hedge funds own PRCT?
3 specialist biotech hedge funds currently hold PRCT, including Driehaus Capital, Perceptive Advisors, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy PRCT?
Eventide Asset Management's position in PRCT was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's PRCT position increasing or decreasing?
Eventide Asset Management completely exited their PRCT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PRCTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →